Comparing how well abrocitinib and dupilumab treat atopic dermatitis signs and symptoms: a plain language summary
Abstract
What is this summary about?
Atopic dermatitis (AD, also called atopic eczema) is a skin disease that that can affect a person for a long time and causes red or flaky skin that can be itchy and uncomfortable. Healthcare providers can prescribe medicated creams and ointments to reduce the visible signs and symptoms of AD, but these treatments are not always enough to keep it under control. A new medicine called abrocitinib is taken every day as a tablet. Abrocitinib works by slowing a part of the body's defense mechanism, called immune response, that is not functioning properly in AD. The clinical study described in this plain language summary, called JADE DARE, investigated how well and how safely 26 weeks of treatment with abrocitinib worked in adults with AD compared to an injected medicine, called dupilumab, that is also approved for AD.
What were the results?
The study showed that abrocitinib was more effective than dupilumab in providing itch relief after 2 weeks. In addition, people who were taking abrocitinib for 4 and 16 weeks experienced greater improvement in the visible skin signs of AD than people who were taking dupilumab. The number of people who had health complaints while taking abrocitinib was similar to the number of people who had health complaints while taking dupilumab. Most of these complaints were minor.
What do the results mean?
Abrocitinib was more effective than dupilumab in quickly improving the signs and symptoms of moderate or severe AD in people who did not show improvement with prescribed medications like creams or ointments.
Clinical Trial Registration:NCT04345367 (ClinicalTrials.gov)
This is an abstract of the Plain Language Summary of Publication article.
To read the full Plain Language Summary of this article, click here to view the PDF.
Link to original article here
Acknowledgments
Pfizer and the study authors thank all the people who took part in these studies. Writing support for this summary was provided by Renee Gordon, PhD, and Vojislav Pejović, PhD at ApotheCom, San Francisco, CA, USA, and was funded by Pfizer.
Financial & competing interests disclosure
KR has served as adviser, paid speaker, or has participated in clinical trials sponsored by Pfizer, AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Forward Pharma, Gilead, Galderma, Janssen-Cilag, Kyowa Kirin, LEO Pharma, Lilly, Medac, Novartis, Ocean Pharma, Sanofi, and UCB, and is cofounder of Moonlake Immunotherapeutics. JPT is an adviser, investigator, or speaker for Pfizer, AbbVie, Almirall, Eli Lilly, LEO Pharma, Regeneron, and Sanofi Genzyme. AB has served as a scientific adviser or clinical study investigator for Pfizer, AbbVie, Abcentra, Aligos, Almirall, Amgen, Arcutis, Arena Pharmaceuticals, Aslan, Athenex, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, EcoR1, Eli Lilly, Evommune, Forté Pharma, Galderma, Incyte, Janssen, Landos, LEO Pharma, Novartis, RAPT Therapeutics, Regeneron, Sanofi Genzyme, Sun Pharma, UCB, and Vibliome. KE is an adviser, investigator, or speaker for Pfizer, AbbVie, Almirall, Bristol Myers Squibb, Janssen, LEO Pharma, Lilly, Novartis, Sanofi, and UCB. WS has been an adviser or clinical investigator, has received speaker's honoraria, consulting fees, or grants, or has participated as a clinical investigator for Pfizer, AbbVie, Aimmune, Amgen, AstraZeneca, Galderma, Genentech, GlaxoSmithKline, Incyte, LEO Pharma, Novartis, Regeneron, Sanofi, and Teva. ZPR is an advisory board member for Pfizer, Biotech, Cassiopeia, and Medscape, a consultant for Pfizer, Brickell Biotech, Cassiopeia, Dermira, and Regeneron Pharmaceuticals/ Sanofi, has received funding from AbbVie, Anacor Pharmaceuticals, Celgene, Galderma, Merck & Co, and Regeneron/Sanofi-Genzyme, and has been a speaker for Pfizer, Dermira, the International Hyperhidrosis Society, PRIME, and Regeneron Pharmaceuticals/Sanofi. HC-hH is a researcher, consultant, or adviser for Pfizer, AbbVie, Amgen, Arcutis, Bausch Health, Boehringer Ingelheim, Bristol Meyers Squibb, Celgene, Dermavant, Dermira, DS Biopharma, Galderma, GlaxoSmithKline, Incyte, Janssen, LEO Pharma, Lilly, MedImmune, Novartis, Regeneron, Roche, Sanofi Genzyme, and UCB. NK has received honoraria as a speaker or consultant for AbbVie, Celgene Japan, Eli Lilly Japan, Janssen Pharma, Kyowa Kirin, LEO Pharma, Maruho, Mitsubishi Tanabe Pharma, Sanofi, and Taiho Pharmaceutical, and has received grants as an investigator from AbbVie Maruho, Eli Lilly Japan, Kyowa Kirin, LEO Pharma, Mitsubishi Tanabe Pharma, Sanofi, Sun Pharma, and Taiho Pharmaceutical. FV has served as an adviser, paid speaker, or has participated in clinical trials sponsored by Pfizer, AbbVie, Amgen, Janssen-Cilag, LEO Pharma, Lilly, Novartis, and Sanofi. MD, TAB, FZ, and HV are employees and shareholders of Pfizer. RR is a former employee of Pfizer. CC is an employee and shareholder of Pfizer. UK is an employee and shareholder of Pfizer Pharma.
Who sponsored this study?
The JADE DARE study was sponsored by Pfizer Inc (the manufacturer of abrocitinib). Sponsoring means that Pfizer Inc designed the study, by working together with the government (for example, with the US Food and Drug Administration) and experts in AD. Pfizer Inc also organized the study and paid the expenses needed for the study's conduct.
Disclaimer
The medicine that was tested in this study, abrocitinib, is approved in some geographic regions for treating people with moderate-to-severe atopic dermatitis, for example, in North America, Europe, and Japan. The results of this study may differ from those of other studies. Healthcare providers should make treatment decisions based on all available evidence, not on the results of any single study.
Open access
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/
